|
|
|
|
|
|
|
|
|
|
|
|
|
27.11.25 - 12:06
|
AKTIONÄR-Top-Tipp Merck & Co: Großes Comeback läuft (Der Aktionaer)
|
|
|
Die Aktie des amerikanischen Pharma-Riesen Merck & Co hat sich in den zurückliegenden Handelswochen prächtig entwickelt. Seit der Vorstellung als "Top-Tipp" in Ausgabe 42/25 (08. Oktober) beläuft sich das Kursplus bereits auf 20 Prozent. Und die Chancen stehen gut, dass sich das Comeback von Merck & Co an der Börse fortsetzen wird....
|
|
|
|
|
|
|
25.11.25 - 17:06
|
EdgeOne Medical Announces Appointment of Marty Shelton as Chief Operating Officer to Strengthen Operational Excellence and Growth Strategy (Business Wire)
|
|
|
WHEELING, Ill.--(BUSINESS WIRE)--EdgeOne Medical, a professional service organization specializing in development and testing services for combination products in the bio-pharmaceutical industry, is pleased to announce the appointment of Marty Shelton as Chief Operating Officer (COO).
Marty Shelton brings over 30 years of extensive experience in pharmaceutical, biotechnology, and life sciences operations. Throughout his career, he has built and led high-performing teams, championed regulatory compliance efforts, and driven sustainable business growth. His leadership roles span quality control, laboratory operations, technical process improvement, and executive-level operational excellence.
Mr. Shelton has held pivotal leadership positions at premier life sciences organizations including Merck & Co., Shire Pharmaceuticals, Alcami Corporation, and most recently, Pace Analytical Life Sciences. His deep expertise in laboratory operations, regulatory compliance, and operational excellence has resulted in measu...
|
|
|
|
|
24.11.25 - 12:48
|
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches (Business Wire)
|
|
|
First presentation for MK-1045, a novel CD19xCD3 T-cell engager in patients with certain types of leukemia and lymphoma, and for bomedemstat, an LSD1 inhibitor, in patients with polycythemia vera
New data demonstrate continued progress with nemtabrutinib, an investigational non-covalent BTK inhibitor
RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to advancing clinical research in hematology across Merck's expanding and diverse pipeline of investigational candidates, with more than 20 abstracts being presented.
“The data we're sharing at ASH 2025 reflect the continued growth and evolution of our promising hematology pipeline,” said Dr. Gregory Lubiniecki, vice pre...
|
|
|
|
|
21.11.25 - 15:42
|
Merck & Co Aktie: Patentablaufverzögerungsspritze (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Merck-Aktienanalyse von der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), rät in einer aktuellen Aktienanalyse die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) weiterhin zu kaufen. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
18.11.25 - 17:33
|
Merck Announces First-Quarter 2026 Dividend (Business Wire)
|
|
|
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every d...
|
|
|
18.11.25 - 13:39
|
AKTIONÄR-Top-Tipp Merck & Co: Kurssprung – da geht noch mehr (Der Aktionaer)
|
|
|
Mit einem Kursplus von rund 3,5 Prozent setzt sich die Aktie von Merck & Co in einem schwachen Gesamtmarkt an die Spitze im US-amerikanischen Leitindex Dow Jones. Frische Studiendaten verhelfen dem defensiven Titel zu einem erneuten Kurssprung – und die milliardenschwere Übernahme von Acceleron Pharma zahlt sich weiter aus....
|
|
|
18.11.25 - 11:01
|
Merck & Co Aktie: Mega-Deal mit Cidara entfacht neue Kursfantasie (Aktiencheck)
|
|
|
Charlotte (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Bank of America (BofA):
BofA-Analyst Tim Anderson habe das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 98 auf 105 USD angehoben und das "buy"-Rating bestätigt. Der Deal mit Cidara werde als vernünftig bezeichnet, da das experimentelle Grippemittel des Unternehmens ein neuartiges Asset mit hoher technischer Erfolgschance darstelle und zudem gut zu Mercks Infektionskrankheiten-Portfolio passe, Zudem sei die Merck-Aktie, angesichts des Wachstums, das der US-Pharmakonzern kurz- wie langfristig liefern dürfte, aktuell zu günstig bewertet, heiße es in einer aktuellen Research Note. [mehr]...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
